Key Takeaways:
- Q2 adjusted EPS $2.58, up 42.5% year over year, beating consensus by 39.4%
- Health Care Benefits AOI $2.4B, medical benefit ratio improved to 87.4%
- 2026 EPS guidance raised to $7.90-$8.10 from $7.30-$7.50
Quay lại
CVS Health EPS jumps 42% on Aetna recovery, lifts 2026 guidance
CVS Health reported Q2 adjusted EPS of $2.58, up 42.5% year over year and beating consensus by 39.4%, driven by Aetna's margin recovery.
"The cumulative impact of these actions in Aetna and Caremark is starting to come through clearly in our results," CEO David Joyner said.
Revenue reached $106.1 billion, up 7.3% year over year and 6.7% above the $99.41 billion consensus. Adjusted operating income rose 35.4% to $5.16 billion, beating estimates by 30.6%. Operating margin expanded to 4.4% from 2.4% a year earlier. Health Care Benefits generated more than $37 billion in revenue, with adjusted operating income of approximately $2.4 billion and a medical benefit ratio of 87.4%, down from 89.9% in the prior-year quarter.
Management raised full-year adjusted EPS guidance to $7.90-$8.10 from $7.30-$7.50, with Health Care Benefits AOI now expected at $5.03-$5.37 billion, more than $1 billion above prior guidance. Operating cash flow guidance rose to at least $11.5 billion from $9.5 billion, supporting further deleveraging after the company ended the quarter with a leverage ratio of about 3.5 times.
Medical membership stood at approximately 26 million at quarter end, flat sequentially but down roughly 700,000 year over year, reflecting the planned exit from the Individual Exchange business. Growth in government business and commercial fee-based membership partially offset the decline. Same-store sales rose 2.6%, down from 15.4% in the prior-year quarter, as script share gains from Rite Aid normalize.
On the earnings call, analysts pressed management on the sustainability of Aetna's improved margins, the durability of pharmacy growth as Rite Aid share gains normalize, and the impact of the 340B program on Health Services. CFO Brian Newman expressed confidence in enterprise earnings growth, while President Prem Shah pointed to specialty pharmacy and biosimilars as mitigating factors.
The company faces headwinds from the 340B drug pricing program and pharmacy benefit manager contract transitions expected to pressure 2027 results. Management also flagged lower Caremark membership next year as it takes a more disciplined approach to contract renewals. Peers Cigna and UnitedHealth Group also raised their 2026 outlooks after reporting stronger-than-expected quarters.
Shares traded at $93.52, down from $104.42 before the earnings release, though the stock has risen 38.4% over the past year compared with 12.2% for the industry. The stock trades at 0.29 times forward sales versus the industry average of 0.52 times, reflecting the market's cautious stance on the recovery's durability.
The guidance raise shows management expects Aetna's recovery to hold through the second half, though the medical benefit ratio is projected to rise materially as the company takes a prudent view of second-half medical costs. Investors will watch the pace of GLP-1 adoption across funded and direct-to-consumer channels, along with AI-driven cost savings from the $20 billion decade-long technology commitment.
This article is for informational purposes only and does not constitute investment advice.
[1] CVS' Q2 EPS Gains From Improved Health Care Benefits Profitability[2] The Top 5 Analyst Questions From CVS Health’s Q2 Earnings Call[3] CVS' Q2 EPS Gains From Improved Health Care Benefits Profitability - August 17, 2026 - Zacks.com[4] Can CVS Sustain Its 2026 Recovery After Raising Earnings Guidance? - The Globe and Mail
